Investigating small molecules that target specific proteins in leukemia cells
Modulate Cullin-RING E3 ubiquitin ligases by small molecule agents
This study is looking at new ways to create small drugs that can help fight certain types of leukemia by targeting a specific protein that can be harmful when it's not working properly, and they want to see how well these drugs work in lab tests and animal models.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10880378 on NIH RePORTER |
What this research studies
This research focuses on developing small molecule agents that inhibit a specific protein complex known as Cullin-RING E3 ubiquitin ligase 4 (CRL4), which has been found to be toxic to certain leukemia cell lines with low levels of a component called cullin 4. The researchers aim to enhance these inhibitors through synthetic chemistry and to understand how they work at a molecular level. Additionally, they will create pre-clinical models using cells and animals to test the effectiveness of these inhibitors against leukemia characterized by low cullin 4 levels. This approach could lead to more targeted and effective treatments for specific types of leukemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia (AML) who have low levels of cullin 4 expression.
Not a fit: Patients with leukemia types that do not express low levels of cullin 4 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies for patients with certain types of leukemia, potentially improving treatment outcomes.
How similar studies have performed: Other research has shown promise in targeting similar protein complexes for cancer treatment, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Pan, Zhen-Qiang — Icahn School of Medicine at Mount Sinai
- Study coordinator: Pan, Zhen-Qiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.